The Effect of Rosiglitazone on Vascular Function in Patients with Advanced Chronic Kidney Disease

Raine Medical Research foundation (pending)0 个研究点目标入组 70 人开始时间: 2005年10月25日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•All patients on haemodialysis or peritoneal dialysis for Chronic kidney disease, Patients should be stable on dialysis for at least 6 months with adequate indices of dialysis (Fractional Reduction of Urea, FRU > 0.67 or Kt/V > 0.3); All patients with moderate-to-severe stages 3-5 chronic kidney disease (GFR < 60ml/min); Patients will be selected for having the Metabolic Syndrome as defined by the WHO criteria [31] based on our previous data showing that these patients had markedly impaired vascular function:1. Insulin resistance identified by 1 of the following: Type 2 diabetes, impaired fasting glucose > 6.1 mmol/L, impaired glucose tolerance or increased fasting insulin > 75th percentile for the population (8 mU/L).PLUS ANY 2 OF THE FOLLOWING:1. Antihypertensive medication and/or systolic blood pressure >= 140mmHg or diastolic blood pressure >= 90 mmHg.2. Plasma triglycerides > 1.7 mmol/L3. HDL-cholesterol < 0.9 mmol/L in men and < 1.0 mmol/L in women4. Body mass index > 30 kg/m2 and/or waist:hip ratio > 0.9 in men and 0.85 in women5. Urinary albumin excretion rate >= 20 microg/min.

•Type 1 diabetes mellitus; Nephrotic-range proteinuria; Liver enzymes > 2 times upper limit of normal; Alcohol consumption > 3 standard drinks/day; Immunosuppressive therapy for renal transplantation; Cardiovascular event or unstable cardiovascular disease in preceding 6 months; Symptomatic or NYHA heart failure stage III or IV; Hb < 110g/L; Significant psychiatric disorder; Active infection or inflammation.

发起方

Raine Medical Research foundation (pending)